Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study

Background Hepatocellular carcinoma (HCC) recurrence rates following locoregional treatment are high. As multireceptor tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors (VEGFRs) are effective in advanced HCC, we assessed the efficacy and safety of neoadjuvant systemic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2021-10, Vol.26 (10), p.854-864
Hauptverfasser:	Woei‐A‐Jin, F.J. Sherida H., Weijl, Nir I., Burgmans, Mark C., Fariña Sarasqueta, Arantza, Wezel, J. Tom, Wasser, Martin N.J.M., Coenraad, Minneke J., Burggraaf, Jacobus, Osanto, Susanne
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis inhibitors Angiogenesis Inhibitors - therapeutic use Benzimidazoles Biomarker Cancer Carcinoma, Hepatocellular - drug therapy Care and treatment Diagnosis Dosage and administration Drug therapy Female Hepatobiliary Hepatoma Humans Hypertension Inflammation Liver diseases Liver Neoplasms - drug therapy Liver Transplantation Living Donors Multireceptor tyrosine kinase inhibitor Neoadjuvant Therapy Neoplasm Recurrence, Local Perfusion computed tomography Placenta Growth Factor Quality of life Quinolones Testing Transplantation of organs, tissues, etc Tyrosine Vascular endothelial growth factor Vascular Endothelial Growth Factor A
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!